The LEO Foundation Award 2014 – Silver Award

Grantee: Dr. Christina Zielinski

Amount: DKK 500,000

Grant category: LEO Foundation Awards

Year: 2014

Geography: Germany

Presented to Dr. med. Christina Zielinski, research group leader and dermatological fellow, Department of Dermatology and Allergology and Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Berlin.

Dr. Zielinski’s research focuses on how the body’s immune system protects itself from microbial assault by distinguishing between the body’s own cells and foreign organisms. It examines what happens when the body does not regulate itself in this way and how this affects the development of autoimmune diseases such as psoriasis and multiple sclerosis. Insights gained from these studies are expected to identify molecular cues that can be exploited in order to develop immune modulation therapies.

The LEO Foundation Award 2014 – Gold Award

Grantee: Dr. Kim B. Jensen

Amount: DKK 1,000,000

Grant category: LEO Foundation Awards

Year: 2014

Geography: Denmark

Presented to Ph.D. Kim B. Jensen, associate professor at the Biotech Research and Innovation Centre at the University of Copenhagen.

Dr. Jensen’s research focuses on how the epidermis, the outer layer of the skin, is constantly renewed throughout life in an organised manner by epidermal stem cells. Epidermal stem cells need to be carefully controlled as any imbalance is likely to have devastating consequences. Too little contribution from the stem cells can lead to bleeding ulcers, whereas too much contribution can lead to skin cancer. By examining how stem cells are regulated in the epidermis, Jensen hopes to gain insights into mechanisms responsible for disease development and identify new drugable pathways.

Psoriasis in children

Grantee: Professor Lone Skov, Department of Dermato-Allergology, Gentofte Hospital

Amount: DKK 4,500,000

Grant category: Research Grants in open competition

Year: 2014

Geography: Denmark

Psoriasis is a chronic inflammatory skin condition with a prevalence of 2-3% in northern Europe. While considerable research exists on adults with psoriasis, there is little research on the condition in children. Identifying key factors associated with psoriasis in childhood may lead to more effective control and possibly even prevention of the condition.

The study aims to determine environmental and genetic risk factors relating to the development of psoriasis in children, the nature of stress related to the child and family, and quality of life. The project also aims to determine the link with risk factors of co-morbidity and the effect of early intensive treatment.

The study is led by Professor Lone Skov, Department of Dermato-Allergology, Gentofte Hospital, Denmark. The team will explore the following hypotheses:

  • Risk factors for early onset of psoriasis can be predicted
  • Early debut of psoriasis has a significant impact on quality of life and individual and family-related stress
  • Early intensive treatment leads to remission
  • There is already an increased risk of co-morbidity in children with psoriasis
  • Age at debut, risk factors and co-morbidity are related
    to the genetic risk.

The study offers a unique possibility to access data from children with psoriasis shortly after diagnosis, which in turn can pave the way for new and improved tools for assessing the impact of the condition on quality of life in a well-controlled study design.

The LEO Foundation Award 2013 – Silver Award

Grantee: Dr. Muzlifah Haniffa

Amount: DKK 500,000

Grant category: LEO Foundation Awards

Year: 2013

Geography: United Kingdom

Presented to Muzlifah Haniffa, Wellcome Trust Clinical Intermediate Fellow in Dermatology at the Institute of Cellular Medicine, Newcastle University, UK.

Dr. Haniffa’s research focuses on dendritic cells; a type of white blood cells also present in the skin that are important in regulating immune responses against microorganisms, cancer and tolerance to self-proteins. Her research has the potential to lead to enhanced vaccination strategies against cancer, such as melanoma, and infections.

The LEO Foundation Award 2013 – Gold Award

Grantee: Dr. Onur Boyman

Amount: DKK 1,000,000

Grant category: LEO Foundation Awards

Year: 2013

Geography: Switzerland

Presented to Onur Boyman, Professor, Dr. med., Senior Consultant Physician and Head of Laboratory at the Department of Dermatology, University Hospital Zurich.

Professor Boyman’s research focuses on the function of T cell subsets and different cytokines in the pathogenesis of psoriasis and other immune-mediated diseases and the treatment of melanoma. His research shows great promise both as a potential treatment of autoimmune and inflammatory diseases and as a potential cancer therapy.

Identification and Characterization of Key Itch Mediators and Receptors in Human Pruitus

Grantee: Professor Martin Steinhoff, University of California San Francisco

Amount: USD 388,225

Grant category: Research Grants in open competition

Year: 2013

Geography: USA

Itch is probably the most common symptom in dermatology and it is associated with a significant impact on the patient’s life.

A team led by Professor Martin Steinhoff, University of California San Francisco, has set out to develop novel targeted therapies for chronic itch in humans.

Besides the lesional and non-lesional as compared to healthy skin, the project team will also identify critical itch mediators and/or receptors that are expressed (and activated) in human dorsal root ganglion (DRG) and spinal cord tissue. To address this, mediators will be identified as well as receptors associated with human itch, and thereby the team will be able to define “biomarkers” for the different pruritic human diseases.

The project will be the first-of-a-kind study to analyse the expression and distribution of key itch mediators and receptors in human skin, human DRG and human spinal cord, and will therefore provide a significant basis for future translational research that targets these mediators/receptors in the different subtypes of itch.

Moreover, it is the first time that it will be tested whether several new itch pathways that have been described in murine skin models are relevant, i.e. can be translated, in human disease state.

Care for chronic skin diseases with a patient-centric approach

Grantee: Professor Lieve Brochez, University of Ghent

Amount: EUR 330,000

Grant category: Research Grants in open competition

Year: 2013

Geography: Belgium

Skin cancer is currently the most frequent type of cancer. At present, life-time risk is estimated at one in six and, with an ageing population, this is expected to increase even more. It is assumed that early detection allows better cure rates and more cost-effective treatment, and skin cancer thus seems suitable for screening initiatives. However, questions remain about the cost–benefit ratio.

This study is led by Professor Lieve Brochez of the University of Ghent, Belgium. It aims to calculate the actual cost of skin cancer in Belgium, the expected cost with an ageing population and how much early detection of skin cancer could affect these costs.

The team will use the results to develop an internationally applicable health-economic model. The model will allow other European countries to use local data, enabling data to be compared across Europe.

Secondly, the study will evaluate a new skin cancer screening approach to compare the yield of this type of screening to the yield of systematic screening in an asymptomatic population within a well-defined population.

Quality of life will be assessed for all screened persons with skin cancer and/or actinic keratosis in order to generate patient-centric data to evaluate the burden of skin cancer.

Skin Cancer Screening Education Study

Grantee: Professor Dr Eckhard W. Breitbart & Dr Rüdiger Greinert from the Association of Dermatological Prevention, Hamburg, and the Centre of Dermatology, Buxtehude

Amount: EUR 822,880

Grant category: Research Grants in open competition

Year: 2013

Geography: Germany

The Skin Cancer Screening Education Study (SCSES) is an interventional study in Canada to evaluate training of primary-care physicians in skin cancer screening (SCS) with regard to screening outcomes for melanoma and non-melanoma skin cancer.

The study, led by Professor Dr Eckhard W. Breitbart and Dr Rüdiger Greinert from the Association of Dermatological Prevention, Hamburg, and the Centre of Dermatology, Buxtehude, both in Germany, will compare screening outcomes for an intervention region with SCS training to screening outcomes for a control region with no training.

The SCS training is based on the German SCS training, which forms part of the German skin cancer screening programme. The results of the SCREEN project, which was led by Dr Breitbart, provide the strongest scientific evidence to date that population-based skin cancer screening can be effective. This new study will evaluate clinical and epidemiological screening outcomes as well as educational outcomes. Data on potential risks associated with skin cancer screening will also be obtained.

Study results will be published in international publications and presented to the scientific community, public health experts and policymakers at European and international conferences, at roundtables of the European Parliament and national parliaments, and in health committees in the study countries, which include Canada.

Defining the skin and blood biomarkers of pediatric atopic dermatitis

Grantee: Dr. Emma Guttman, MD, PhD, Associate Professor of Dermatology, Director Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine, Mount Sinai, New York

Amount: USD 1,046,400

Grant category: Research Grants in open competition

Year: 2013

Geography: USA

Despite considerable impact on quality of life, atopic dermatitis, or eczema, has not been studied extensively in children although as many as one in five experience the condition. Atopic dermatitis, or eczema, is a chronic skin condition, characterised by itching and inflammation, and frequently occurs in people who have other allergic conditions, such as asthma and hay fever.

Dr. Guttman has set out to define the skin and blood biomarkers of atopic dermatitis in children. She and her team will investigate how skin biomarkers compare to disease activity, epidermal barrier function and known biomarkers in adults with atopic dermatitis. They will also investigate whether blood biomarkers could offer a less invasive way to monitor skin changes than a skin biopsy, which can be difficult to perform in children.

With better knowledge of what causes atopic dermatitis in children, the researchers hope to develop more targeted therapies for the disorder as well as for other atopic conditions, such as asthma and hay fever. Together, these three disorders form an “atopic triad”.

Publications:

Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets

J Allergy Clin Immunol. 2015 Oct; 136(4): 941–951.e3.

Early-Onset Pediatric Atopic Dermatitis Is TH2 but Also TH17 Polarized in Skin

J Allergy Clin Immunol 138 (6), 1639-1651. 2016 Sep 23.

Alterations in B-cell subsets in pediatric patients with early atopic dermatitis

J Allergy Clin Immunol. 2016 Dec 10 pii: S0091-6749(16)31452-X

Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development

J Allergy Clin Immunol. 2016 Nov;138(5):1473-1477.e5

An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.

J Allergy Clin Immunol. 2017 Jan;139(1):152-165

The LEO Foundation Award 2012 – Silver Award

Grantee: Dr. Andrea Chiricozzi

Amount: DKK 500,000

Grant category: LEO Foundation Awards

Year: 2012

Geography: Italy

Presented to skin immunology specialist Dr. Andrea Chiricozzi at the Department of Dermatology, University of Rome Tor Vergata, Italy.

Chiricozzi’s research focuses on chronic skin inflammation and the pathogenic circuits underlying the formation of skin lesions, particularly in regard to psoriasis and atopic dermatitis. The award will support Chiricozzi’s on-going research into the pathogenic mechanisms in skin disorders and novel therapeutic strategies.